OncLive TV

Rupal S. Bhatt, MD, PhD, discusses the discovery of HHLA2/KIR3DL3, a novel therapeutic immune checkpoint pathway in renal cell carcinoma.

Howard S. Hochster, MD, FACP, discusses important takeaways from the randomized, double-blind, phase III POLO trial in pancreatic cancer.

Alexander E. Perl, MD, MS, discusses how to assess what therapy is best for patients with acute myeloid leukemia.

Rutika Mehta, MD, MPH, discusses a phase II trial that will combine ramucirumab with TAS-102 in patients with advanced gastric and gastroesophageal junction cancer.

Denise Yardley, MD, discusses the impact of biosimilars on breast cancer treatment.

Gary H. Lyman, MD, MPH, discusses granulocyte colony-stimulating factor biosimilars and their impact on the market.

Robert G. Uzzo, MD, MBA, FACS, discusses the evolving role of surgery in metastatic kidney cancer.

Nabil Djouder, PhD, discusses the role of liver regeneration in hepatocellular carcinoma.

Tim F. Greten, MD, discusses the role of the gut microbiome in antitumor immunity in liver cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses the implications of the randomized phase III APACT trial evaluating gemcitabine alone versus gemcitabine plus nab-paclitaxel as adjuvant therapy in patients with pancreatic cancer.

OncLive interviewed experts at the State of the Science Summits™ in September 2019 on anticipated research to be presented at the 2019 ESMO Congress.

John M. Timmerman, MD, discusses recent developments made in the treatment of patients with Hodgkin lymphoma.

David E. Avigan, MD, discusses research surrounding CAR T-cell therapy in lymphoproliferative diseases.

Noelle Frey, MD, MSCE, discusses the use of CAR T-cell therapy in acute lymphocytic leukemia.

Donald A. Richards, MD, PhD, discusses the secondary endpoints of the randomized, double-blind, phase III POLO trial, which evaluated maintenance therapy with olaparib in patients with germline BRCA-mutated, metastatic pancreatic cancer.

Ali McBride, PharmD, MS, BCOP, discusses the oncology community’s reaction to biosimilars for rituximab (Rituxan).

Wells A. Messersmith, MD, discusses therapeutic options in metastatic colorectal cancer and what factors help determine the most appropriate option.

Imad Tabbara, MD, discusses the expansion of treatment options for patients with acute myeloid leukemia.

Randal H. Henderson, MD, MBA, discusses accessibility of proton therapy versus intensity-modulated radiation therapy in prostate cancer.

Michael Wang, MD, discusses data from a phase I/II study looking at the use a triplet regimen of vorinostat, cladribine, and rituximab in patients with newly diagnosed mantle cell lymphoma.

Andrew D. Zelenetz, MD, PhD, discusses approved treatment options for patients with mantle cell lymphoma, as well as treatments coming down the pipeline.

Wayne A. Marasco, MD, PhD, discusses ways CAR T cells are being engineered to avoid on-target adverse events in solid tumors.

Manish Kohli, MD, discusses the challenges of molecular classification in prostate cancer.

Heinz-Josef Lenz, MD, FACP, discusses updated results from the phase II CheckMate-142 trial in metastatic colorectal cancer.

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses current treatments in ESR1-mutant breast cancer.

Richard S. Finn, MD, professor of clinical medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles (UCLA), and Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA, discusses the rationale for the phase III KEYNOTE-240 trial in hepatocellular carcinoma (HCC).

Gary H. Lyman, MD, MPH, discusses challenges in biosimilar policies.

Matthew P. Goetz, MD, discusses adverse events associated with aromatase inhibitors.

Enriqueta Felip, MD, discusses immunotherapy alone versus immunotherapy plus chemotherapy in patients with lung cancer.

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses challenges with biomarkers in renal cell carcinoma (RCC).